In hospital she was treated with droperidol and procyclidine. Whilst manic she was overactive, and slept little. She denied fatigue. Four weeks later when euthymic she could still perform activities not attempted for more than a year. These included long walks, cycling, and badminton, none of which now caused her pain or undue fatigue. She remained well over the following month, medication was discontinued, and she returned home.
Discussion
This case illustrates recovery of CFS following mania. Why did she recover? Could the coincidence of mania and recovery have been due to chance? We think that this is unlikely given the chronicity of her condition. Could the antidepressant have been a common factor causing both mania and recovery? Antidepressants can probably trigger mania'°.
There is also anecdotal evidence that they can reduce disability in CFS, and good evidence in a similar condition called fibromyalgia". However, we consider it more likely that elevation of mood caused her recovery. Increased energy and immunity to fatigue have long been observed during mania'2, but the persistence of recovery suggests a more permanent change in factors maintaining her disability.
Depression is one possible factor. This possibility is supported by the history of overdose, intermittent low mood and impaired energy and concentration. Furthermore, the development of mania suggests a bipolar predisposition. Against are the negative psychiatric assessments. The case for a primary depressive disorder is therefore unproven and presupposes an atypical or 'masked' presentation. Psychosocial factors'3 may also maintain disability. A belief that (benign) activity associated symptoms indicate damage may lead to avoidance of activity and hence to disability'4. Family members may reinforce both beliefs and avoidance. There is evidence that similar fears can be reduced by elevation of mood".
We suggest that the clinical assessment of patients presenting with CFS should consider not only physical pathology, but also mood, beliefs, avoidance of activity, and the role of the family. To develop and market a new chemical entity (NCE) can now take 10-12 years and cost £100 million or more. On 19 March 1990, representatives of the pharmaceutical industry, the UK regulatory authority and Government met at the Royal Society of Medicine to discuss the difficulties encountered in new drug development at all levels and to recommend possible solutions.
The morning session, entitled 'How is industry improving its development process?', was chaired by Dr David Jack (ex-Chairman and Chief Executive, Glaxo Group Research).
Thinking strategically
As the first speaker, Dr Tony Kennedy (Project Director, SmithKline Beecham) pointed out that strategic reappraisal of projects as they move forward from research to development and during development itself is essential to ensure that the talents and resources of a company are concentrated upon projects of real value. He emphasized the importance of the product profile, which defines the expectations for a new product in terms of its efficacy, safety, dosing regimen, presentation and labelling and can be used as a strategic tool to assess the impact of development findings and external events upon the commercial opportunity. 'Gold' standards of therapy frequently change during the development of an NCE rendering an earlier target product profile obsolete; the use of HMG CoA reductase inhibitors in the treatment of hypercholesterolaemia and ACE inhibitors in congestive heart failure were quoted as examples. Equally, information derived from studies of clinical efficacy and safety or long term toxicology may result in a reappraisal of the medical and commercial opportunity for a drugperhaps leading to termination of the project. The failure of the majority of NCEs to repay their development costs would seem to indicate that such painful decisions are frequently not taken. The Royal Society of Medicine Commercial appraisal The marketeer's viewpoint was presented by Mr lain Ross (Managing Director, Reed Healthcare Communications; previously Associate Director, Roche Products) who stressed the importance of ensuring the overall commercial viability of an NCE before a decision is made to enter clinical development. Accurate commercial input is often not solicited until midway through development, by which time considerable resources have already been committed. When commercial input is requested, pharmaceutical marketeers frequently fail to provide a meaningful and realistic evaluation. He described the analytical steps which should be followed to develop a minimum competitive profile. The target market is first segmented in terms of diagnosis and type of prescriber. For innovative drugs such as 5HT3 antagonists, likely to create a new therapeutic category, some early market research is essential. Most new drugs however are for existing applications, and must be compared with products of similar safety, efficacy, convenience and price. A key analysis is that of 'patient flow' -the series of stages from a patient's initial visit to a general practitioner, through referral to a specialist, to decisions about treatment and dosage. By mapping out this sequence, it is possible to identify the potential for growth in the market that may arise because of changes in the patient population, the prescribers and the way the drug is used; the optimal levels of promotion can be determined and the essential elements of the product profile, which are critical to achieving the maximum return on investment, defined. Whilst medical and commercial needs do not always coincide, for instance in the development of orphan drugs, a greater commercial awareness is needed at an early stage in development in order that companies can be realistic in their assessment of the potential for new compounds.
Protecting the asset An intellectual property law perspective was provided by Mr David Llewelyn (Partner, McKenna & Co). He described the various methods for protecting ideas and products: patents and trade marksthe most effective methodsand also copyright and registered designs (of minor importance to the pharmaceutical industry). Currently, a patent in most Western European countries confers a protection of 20 years from the date on which the application was filed. US patents last for 17 years from their grant, which may be several (5 or 6) years from the application date. However, once the product licence has been granted, this period of protection is generally reduced to less than 8 years. Approval of a proposal currently being debated by the European Commission would extend the 'patent life' of pharmaceuticals to 16 years from the date of marketing authorization. A patent gives the patentee a monopoly protection during its life but it is up to the patentee to enforce his rights by detecting infringements and taking legal action. Mr Llewelyn explained how EEC law affects intellectual property rights. Parallel imports are perhaps the best-known area where conflicts between European ideals and intellectual property rights have produced uncertainty and consequent litigation. In a typical case, the same product is marketed by a manufacturer or associated companies in different countries, either under the same or under different names. Price differentials may arise between different national markets and these differentials are exploited by parallel importers.
Focusing the development plan Dr Kevin Young (International Affairs, ABPI; previously International Clinical Project Manager, Bayer) identified the important features of the coordination of drug development from the start ofthe clinical phase to the time ofregistration: a 'consumeroriented' development plan which is based on scientific/ medical criteria and regulatory requirements, a balanced multidisciplinary project team to plan and review progress, and experienced managers to coordinate the team's efforts and to ensure the effective flow of information between internal departments and hierarchies. Development is a dynamic process and unforeseen events can result in the need to change course. To some extent, the fate of the whole project is always at risk. It has been estimated that, of 100 Investigational New Drugs submitted to the FDA, only 20 survive up to and beyond the New Drug Application (NDA) stage. Around 70% are abandoned for a variety of reasons (lack of efficacy, pharmacokinetic inadequacy, minimal advantage over competitors, high risk/benefit ratio, intolerance) before the end of Phase II clinical trials. The project team must be prepared to recommend that the project be abandoned to protect further clinical trial patients from unnecessary treatment and to allow the-company td divert its resources to more promising projects, but it is equally important to avoid premature action which might ultimately deny patients treatment with a valuable new drug. If companies can create an environment which allows project team work to flourish, preserving trust and good communications but minimizing bureaucracy, this -combined with a well founded development planshould lead to better coordination of the industrial aspects of new drug development.
Role of product development Dr Kevin Bilyard (International Medical Planning
Manager, ICI Pharmaceuticals) described the cangin healthcare environment, pointing out that expectations of new therapeutic products are becoming increasingly polarized. On the one hand society at large demands effective remedies that provide rapid symptomatic reliefwith no risks and with little regard for cost; confidence in medical judgement as a controlling mechanism is high. National governments, on the other hand, will employ more sophisticated economic analysis in conjunction with traditional technical measures when evaluating the benefits of potential new medicines. Cost containment is a major force and cost-benefit analysis will become a significant factor in the approval process. These two positions need to be reconciled with the fact that a company's level of investment in R&D will continue to be a function of overall business performance. Cost effectiveness will become increasingly important in an ever more competitive market place. To ensure continued success, the need for efficient project management processes can only increase.
Dr Bilyard suggested that the pharmaceutical industry could implement many of the principles which had underpinned significant productivity improvements in manufacturing organizations during recent years. The benefits of this more structured management framework would be amplified given the complex transnational nature of pharmaceutical product development.
The second session of the meeting considered the regulatory and government viewpoints and was followed by a panel discussion. The Forum's chairman, Dr John Mucklow, (City General, Stoke-on-Trent) chaired the proceedings.
Government perspective
Mr Bryan Rayner (Deputy Secretary, Department of Health) described how the Government contributes to the encouragement of new drug research in three areas of medicines policylicensing, pricing and prescribing. The undoubted success of the British pharmaceutical industry was highlighted by the statistic that, in 1988, eight of the world's top 20 selling medicines were a result of UK research. He reported that the Medicines Control Agency (MCA) had recently cut the assessment time for innovative drugs to 99 days, making the UK the fastest licensing authority in the European Community for the registration of new compounds. For variations of existing licences and abridged applications, he noted that problems remained but that encouraging progress had already been made. He explained that the establishment of the MCA was prompted by an independent study of the former Medicines Division. This reported that 'the overall record of medicines control in the UK was good and its reputation deservedly high' but criticized the management arrangements. The MCA was now being organized into six multi-disciplinary businesses, all to be headed by managers with proven managerial ability, accountable to the Director for the achievement of challenging targets.
Mr Rayner explained the significance of the pharmaceutical price regulation scheme, unique to the UK, which recognizes the need for continued R&D. A target profitability is set for each company expressed as a return on the capital invested in NHS business. The rate for each company varies within a range, depending on a number of factors, including the risks it incurs through R&D. Manufacturers have considerable freedom over the pricing of new medicines thus allowing them within the profit level set for their company to ensure a quick return on successful R&D. A particular feature of the scheme is its recognition of the need for continued research and development, by allowing as a cost in NHS prices a level of expenditure on R&D significantly higher than the world average. The liberal prescribing policy in the UK was emphasized. By introducing the indicative prescribing scheme, to provide a framework within which the Family Practitioner Committee's Medical Adviser can discuss each practice's prescribing with them, the Government is seeking to promote quality in care rather than cheap prescribing. Evidence shows that GPs who have a relatively high prescribing unit cost but a relatively low prescribing ratein other words tend to use the newer and more expensive drugs-are often the best prescribers. By laying an emphasis on the relative cost-effectiveness of different medicines, the new scheme should actually place a premium on successful innovation.
Regulatory viewpoint
Dr John Purves (Medicines Control Agency) reviewed the current structure of the Agency and the proposed reorganization, into a number of specific businesses each with its own manager. The tasks within each of these businesses would be undertaken by multidisciplinary teams, including for example administrators, physicians, scientists and pharmacists. These steps reflected some of the recommendations put forward by Dr N J B Evans CB and Mr P W Cunliffe CBE, who undertook the 'Study of Control of Medicines'. He indicated that other positive steps had also been taken to introduce new technology, to address staff and personnel issues and to improve procedures within the Agency. Evidence of improvements in the processing of applications for new drugs has already been confirmed. Delays in processing, he stated, were not always the fault of the Regulatory Authority. The speed of assessment by Agency staff and associated Advisory Committees (notably the Committee on Safety of Medicines) is also determined by the quality of the application received: a poorly-presented application may take four times as long as a good one. Dr Purves then reported on various aspects of European harmonization which are leading to improvements in the processing of Multistate and Concertation Applications.
Panel discussion
Professor William Asscher (Chairman, Committee on Safety ofMedicines) opened the discussion. He had a simple message for industry: 'Have a good product, have a good application, have good expert reports and we'll do the job very fast'. Since -assuming his position in 1987, he had halved the number of Committee hearings by encouraging negotiation with industry on receipt of a product licence application (PLA). He had also begun to give industry some feedback regarding the quality of their PLAs. In the last 3 years, he reported, there have been no revocations of licences, the numer of PLAs considered per meeting has increased from 12 to 16 and, to industry's credit, the average number of volumes per PLA has decreased from 170 to 159.
Professor George Teeling-Smith (Director, Office of Health Economics) focused his remarks on the increasing importance of cost effectiveness in a changing healthcare environment, as described by Dr Bilyard. He emphasized the need to determine whether a product is going to produce an economic pay-off, or is going to improve patients' quality of life, or both. Cost effectiveness should be assessed twice: during Phase III clinical trials and again after licensing in order to re-affirm the results. A product which has no economic advantage, he concluded, will be just as difficult to sell as a product that has no clinical advantage. Dr Roger Brimblecombe (Vice President, Collaborative R&D, SmithKline Beecham) commented on two issues: the time taken to develop a drug and the requirement for marketing input. He outlined the reasons why, in 1973, Smith Kline & French were able to develop cimetidine in 4-5 years rather than the currently typical 10-12 years. A major factor was that cimetidine was a novel innovative drug which represented a significant therapeutic advance; investigators were 'falling over themselves' to work with the drug. Smith Kline & French gambled on success and ran studies in parallel; notably,-carcinogenicity studies were started at a very early stage so that these data were not rate limiting. Dr Brimblecombe discussed the importance of the-minimum competitive profile as a contract between marketing and R&D. He suggested that early marketing input for truly innovative drugs should be treated*ith reservation: early projections for cimetidine had been extremely low.
Concluding the panel discubsion, Dr Johii -Toy (Vice President, Clinical R&D, expressed the view that industry is grad6ially succeeding in improing tliiedrug development process. It is learning from past mistakes, attracting, better qualified and higher calibre'staff than before, takig advantage of efficient projecd management systems and modern technology, and improving standards of presentation to regulatory authorities. Meetings such as this one, he commented, can only be helpful.
,The complete proceedings of the meeting will be published in the first two issues of the Journal of Pharmcaceutical Medicine. The investigation of the pathogenesis of human cardiovascular disease is clearly oftgriat importahice in medicine and pharmaology. Cadiovascular diiseas is also observed in donietic And Iaxbotatoryanimals. The meeting ofthe Section of(ComparAtive Medicine considered reviews of drug-induced cardiovascular disease in animals and naturdly-occurring diseases, both animal and human. The clinical and inn vitro methodology availablefbr tlid investigatibn ofcardiac function were also presented'.lTle speakers therefol-e covered a diverse range of topics, iWhiEh had the' common theme of striving to improve ourIxidef standing of cardiovascular disease processes;-Drug-induced artpritis in nimals after treatment with the cyclic AMP phosphodiesterase Im injhibitor (PDI), ICI-145,730, was discussed by Dr Russell Westwood (CI, Alderley Park). In longterm studies in rats arteritis and arterial thickening of mesenteric arteries were observed. Since the incidence of the changes apparently increased after withdrawal of the drug, it was suggested that the lesions were the result of a reparative response. Excessive vasodilatation at high doses would cause stress on the arterial media and the in o y response would be an adaptive process. Withdrawal of compound led to a return to the normal Fate. In chroni4c dog studies, myocardial inflammation, ecrosis in the right atrium and papillary muscle necrptis were prqducqd. It was suggested that the myocarditis and arteriopathy in the dog were due to vasodilatation with a reparative response and that the papillary muscle lesion was due to inotropy and consequent-physical stress in the left, ventricle. These lesions were seen in the minipig but not in primates.
Mr Terry Walker (SmithKlIne Beecham, Welwyn) presented data of the SmithKline and-French investigations of PDIs. After prolonged treatment with these compounds the histoXathology of the arteries was similar to that after exposure to the ICI compounds. Monastral Blue was used to visualize haemorrhage resultng from a single infiusion of SKFP95654 in dogs. Gross haemorrhage was seen iater1I or 3 days; however by 10 days haemorrhagic lesions were only detected microscopically, a,nd by, 34 days lesions were-not observed4,`MonaKral,Blue was thern detected in the intima,*implying repair of an-earfier haemorrliagic lesion. 'Inthis Omdel, haemdrrhage was seen in dogs,.but"not in monkey or pig, whereas inotropy was aen in all species. The pathogenesis ofthese lesions did not appear therefore to be dueto this aspect of the pharmacology of these drugs. It was suggested that the dog. is particularly susceptible to developzent of arterial lesions.
-Dr Michael Levi (Hospital for. S,ick Children, Great Orniond Street) reviewed childhood vascular. diseases with particular. referenge to Kawasaki's dis-ease (K]D), 'which .was first cescribed 20 years.-ago in,J4pn,. The diagnosis is based s, clinical signs, whjinclude fever, diffuse erythema of the skin, -marked reddening, cracki-ng or ulceration of the. lips and peeling of the skin of the hands and.feet during recovery, T`e disease is now recognized.,4 a vasculitis with dilatation and aneurysm ofthevcorqary arteries being of particular concern. In Japan, where over .80 000 children, mnstly,between theigges of one and twQ.years have beenaffected, epidenaics occur. very 2-3 years. This periodicity and a wave-like spread suggest that the disease is due to an infectious agent.
.KD also occurs in the USA and Canaa and is probably underdiagnosed in Britain.--Differential i_clude measles, scarlet fever, staphylocal to,x,ic shock syndrome, enterovirus infection .and Rocky Mountain spotted fever. Mortality is 1-2%, usually,due to thrombosis of a widely dilated coronary artery, A specific aetiological agent has not been idantifiea but recently, toxigenic Proprionobacterium acnes, a skin commensal has been implicated.
.T acute phase of the disease is characterized by an acute inflammatory response, followed by a markedL increase in platelet count and, various platelet-derived vasoactive mediators, Te second phase is associated withf the presence of aneurysms. and a platelet-aggregating factor in the plasma. This process is calcium-dependent, blocked by protacyclin, leads to the release of serotonin from platelets and is probably brought about by immune complexes. 
